Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

News provided by

Apr 07, 2023, 10:30 ET

DUBLIN, April 7, 2023 /PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Dermatology Partnering 2016-2023: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in dermatology partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Dermatology partnering agreement structure
Dermatology partnering contract documents
Top dermatology deals by value
Most active dermatology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering dermatology deals.

The report presents financial deal terms values for dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading dermatology deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to dermatology deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2016. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope

Global Dermatology Partnering 2016-2023 is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

Global Dermatology Partnering 2016-2023 includes:

Trends in dermatology dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to over 700 dermatology deal records
The leading dermatology deals by value since 2016

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

In Global Dermatology Partnering 2016-2023, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Dermatology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 700 dermatology deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Selection of Companies Mentioned

3D Systems
3M Critical & Chronic Care Solutions
23andMe
Abbvie
Accelis Pharma
AccuTec Blades
Acelity
Acell
Aclaris Therapeutics
Actelion
ADB International Group
Adhesys Medical
Advanced BioScience Laboratories
Advanced Medical Solutions
Advanced Plasma Products
Advanz Pharma
Aesthetic Management Partners
Afinity Life Sciences
Aghraas-Cigalah
Air Force Research Laboratory
AiVita Biomedical
Akaal Pharma
Alat Medika Indonesia
Alibaba Health
ALK-Abello
Allergan
Allergan (name changed from Actavis)
Alliance Pharma
Alliqua Biomedical
AlloSource
Almirall
Alpha Pharma
Alvotech
Amarantus BioSciences
American Academy of Professional Coders
American Red Cross
American Skin Association
Amgen
AMI
AMNIOX
Amor (Suzhou) Medical Sci-Tech
AMSilk
Amyris
ANANDA Scientific
Andrew Technologies
Angelini Pharma
AnGes MG
Angionetics
Anika Therapeutics
ANI Pharmaceuticals
Anteis
Anterios
Antibe Therapeutics
AOTI
APL
Applied Biology
APR Applied Pharma Research
Apria Healthcare Group
Aqua Pharmaceuticals
Aralez Pharmaceuticals
Aratana Therapeutics
Arcutis Biotherapeutics
arGEN-X
Arrevus
Arrien Pharmaceuticals
Arsenal Medical
Arthrex
Art of Technology
Aslan Pharma
Astellas Pharma
Astion Pharma
AstraZeneca
ATG Allied Technologies
Athenex
Atopix
Aucta Pharmaceuticals
Austen BioInnovation Institute in Akron (ABIA)
Auven Therapeutics
Avalon Pharmaceuticals
Avaria Health & Beauty
Avita Medical
AvKARE
Axcelon Dermacare
Axonlab
Axxess Pharma
Azitra
Back-A-Line
BASF
Basilea Pharmaceutica
Bassett Salon Solutions
Bausch & Lomb
Bavarian Ministry for Economic Affairs and Media
Energy and Technology
Bayer
Baylor Research Institute
B Braun
Beiersdorf
Bellus Health
Ben-Gurion University
Berkshire Sterile Manufacturing
Berlin-Brandenburg Center for Regenerative Therapies
Berlin Chemie
Best Choice
BexPharm
BGN Technologies
Bill and Melinda Gates Foundation
BioCad Holding
Biocon
BioCryst Pharmaceuticals
BioDerm
BioDlogics
Biogen
BiolineRX
Biomedical Advanced Research and Development Authority
BIOMEDX Group
BioMed X Innovation Center
Biometrix
Biomillenia
Bioniz Therapeutics
Bionpharma
Biophage Pharma
BioPharm Group International
Bioskin
Biosolution
BirchBioMed
Bloomage BioTechnology
BMG Pharmaceuticals
Boehringer Ingelheim
Boragen
Boston Pharmaceuticals
Boston Topicals
BoyaLife
Bpifrance
Brickell Biotech
Brigham and Women's Hospital
Bright Future Pharmaceutical Lab
BSN Medical
Cadila Pharmaceuticals
CALECIM Cosmeceuticals
Caliber Imaging & Diagnostics
Can-Fite BioPharma
CANbridge Life Sciences
Candela
CannaSkin
Cannassure Therapeutics
CanniMed Therapeutics
Cantel Medical (UK)
Capital Laser and Skin Care
Cara Therapeutics
CARB-X
Cardiome Pharma
Carestream Health
Case Western Reserve University
Castle Creek Pharmaceuticals
CDx Diagnostics
Celgene
CellMark Medical
Cell Mogrify
Certara
CHAMPS Group Purchasing
Charite-Universitatsmedizin
Chelexa Biosciences
Chemipal
Chemstar
Children's Hospital Boston
China-Israel Biological Technology
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Chromogenex Technologies
Chugai Pharmaceutical
Cimtech
Cincinnati Children's Hospital Medical Center
Cipher Pharmaceuticals
Cipla
Circadia
CIVCO Radiotherapy
CJ CheilJedang
Clarify Medical
Clinipace Worldwide
CMS Medical
Collagen Solutions LLC
Collagen Solutions Plc
Collplant
Columbia University Medical Center
ConBio (Shanghai)
Contem 1G
ConvaTec
Cook Biotech
Cooper-Vemedia
Cosmotec
Covaleo
Covalon Technologies
Crescita Therapeutics
CROMA Pharma
Cronos Group
Crown Bioscience
Crown Laboratories
Cryolife
Cumberland Pharmaceuticals
CURE Pharmaceutical
Curetis
Cutanea Life Sciences
Cutanogen
Cytori Therapeutics
CytoSorbents
Dabur
Dalhousie University
Daniel Alain Life Science
DASH Analytics
Dasman Diabetes Institute
Daxor
Dechra Pharmaceuticals
Denali Therapeutics
Department of Defence
Department of Defense
Department of Veterans Affairs
DermaConcepts
Dermala
Derma Sciences
Dermata Therapeutics
Dermavant Sciences
Dermelix Biotherapeutics
Dermira
Dermpath Diagnostics
DermSpectra
DermTech
Devonian Health Group
Dinaco
Dipexium Pharmaceuticals
Diplomat
Dr. Falk Pharma
Dr. Reddy's Laboratories
Dr. U Devices
Dr Bragi Company
Dr Kerklaan Therapeutics
DS Healthcare
Ducere Pharma
Dukal
Dynasil
E-QURE
Eccrine Systems
Eclipse Aesthetics
Eirion Therapeutics
Eisai
eKare
Elanix Biotechnologies
Elektrofi
Elev8 Brands
Ember Therapeutics
Emory University
Emphysys
EMS
Enaltus
Encore Dermatology
Encore Medical
Enteris Biopharma
Envy Medical
Enzymatica
Epicore Biosystems
EPI Health
Equillium
Espada Dermatology
EspeRare Foundation
Ethicon Endo-Surgery
Eureka Eurostars
Eurofins Scientific
Eve & Co
Evolva
Ewopharma
Excelra
Exicure
Expanscience
Fagron
Ferrer International
Fidelta
Fillmed
First Horizon Pharmaceuticals
Fission Labs LATAM
Flowerkist
Follicum AB
Food and Drug Administration (FDA)
FormaTK Systems
Fougera Pharmaceuticals
Fujifilm Kyowa Kirin Biologics
Fuji Pharma
G-treeBNT
Galapagos
Galderma
Gebro Pharma
Gecko Biomedical
Geisel School of Medicine at Dartmouth
Gene Biotherapeutics
Genentech
General Biologicals
Genfa Medica
GHD GesundHeits
Givaudan
GlaxoSmithKline
GL Brands
GlobalMed
GPC Systems
Grunenthal
Grupo Ferrer
GtreeBNT
Guangzhou Xiangxue Pharmaceutical
Guthy-Renker
H2-Pharma
Hairmore Group
Hapten Sciences
Harvard Medical School
Hawkeye Therapeutics
Helsinn Healthcare
Hemostasis
Heumann Pharma Generics
Hill Dermaceuticals
Histapharm
Histocell
Histogen
HitGen
Hope Medicine
Hoth Therapeutics
Huapont Pharma
Hugel
Iagnosis
Icahn School of Medicine at Mount Sinai
Ice + Jam
Ichnos Sciences
Ideal Medical Solutions
IDEAYA Biosciences
iFyber
ImaBiotech
Imbed Bio
IME Medical Electrospinning
IMIDomics
Immune Pharmaceuticals
Immunomic
Induce Biologics
Innate Biologics
Innovate UK
Innovation Skane
Innovative Cellular Therapeutics
Innovus Pharmaceuticals
Inova Diagnostics
Institute for In Vitro Sciences
Intalere
Integra LifeSciences
Intermountain Healthcare
Interpolymer/Zschimmer & Schwarz
Intralytix
ISDIN
ISIS Innovation
Isoprene Pharmaceuticals
Israeli National Authority for Technological Innovation
ITEM Medical Technologies
Jackson Laboratory
Janssen Biotech
Janssen Pharmaceuticals
Janssen Pharmaceutica NV
Janssen Research & Development
Japan Tobacco
JCR Pharmaceuticals
Jiangsu Hengrui Medicine
Jiangsu QYuns Therapeutics
Johnson & Johnson Consumer Companies
Johnson & Johnson Innovation
Juntendo University
JW Pharmaceutical
Kaken Pharmaceutical
Kane Biotech
Karo Pharma
Karyopharm Therapeutics
Kavo Kerr Group
Keck School of Medicine of USC
Kent Imaging
Kerecis

For more information about this report visit https://www.researchandmarkets.com/r/chtdja

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Media

Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets